N/A N=30 Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 Chronic Total Occlusion Percutaneous Coronary Intervention Study
Chronic Total Occlusion · Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery
Primary: Number of Participants With Procedure Success — 121 Participants
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
N/A N=100 Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II
Total Atherosclerotic Occlusion of Femoral Artery
Primary: Primary Safety Endpoint — 2 Percent of participants
N/A N=23 Bridge Occlusion Balloon in Lead Extraction Procedure
C.Surgical Procedure; Cardiac · Cardiac Dysrhythmia · Disorder of Pacing Function
Primary: Number of Participants With Successful Balloon Occlusion of Superior Vena Cava — 18; 5 Participants
N/A N=163 The Asahi Intecc PTCA Chronic Total Occlusion Study
Coronary Artery Disease · Coronary Artery Chronic Total Occlusion
Primary: Procedure Success — 119 Participants
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=2,487 ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Coronary Stenosis · Atherosclerosis
Primary: Imaging Outcome (Powered): Minimal Stent Area (MSA) — 5.72; 5.36 mm^2 — p=<0.0001
N/A N=3,000 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
Myocardial Infarction · Acute Coronary Syndrome · Coronary Artery Disease
Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants
N/A N=71 Side Branch FFR After Provisional Stenting
Coronary Artery Disease
Primary: Number of Participants With Side Branch Compromise — 7; 9 Participants
N/A N=15 Coronary Flow Reserve Following Orbital Atherectomy
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio
N/A N=443 Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions
Coronary Artery Disease
Primary: Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) — 89.6 Percent probability of Freedom from MACE
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
Phase 4 N=92 Boston Scientific OffRoad™ Re-entry Catheter System for Subintimal Recanalization of Chronic Total Occlusions in Femoropopliteal Arteries
Chronic Total Occlusion
Primary: Composite Rate of Major Adverse Events — 3.3 percentage of participants
N/A N=37 Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI
Coronary Artery Disease (CAD)
Primary: Index of Microcirculatory Resistance (IMR) — 15; 25 mmHg·s
N/A N=400 Study of the CAT RX Aspiration Catheter When Used in Patients With Large Occlusive Thrombus in Coronary Arteries
Coronary Vessel Occlusion
Primary: Composite of: — 14 Participants
N/A N=450 OPTIMIZE PCI: Multicenter Randomized Trial of OCT Compared to IVUS and Angiography to Guide Coronary Stent Implantation
Coronary Artery Disease
Primary: Primary Efficacy Endpoint (Powered): Post-PCI Median Minimum Stent Area (MSA) — 5.79; 5.89; 5.49 mm^2
Phase 4 N=60 Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Ischemic Stroke
Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >
N/A N=35 The Oxford Optimisation of PCI Study (OXOPT-PCI Study)
Coronary Artery Disease
Primary: Final Fractional Flow Reserve (FFR) After Intracoronary Stenting — 0.80; 0.84; 0.88 Ratio
Phase 4 N=49 APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Myocardial Infarction
Primary: 6-month Reocclusion — 1; 4 participants
N/A N=34 Vis-Rx Prime Micro-Imaging Catheter Study
Coronary Artery Disease
Primary: Technical Performance — 56.0 millimeters — p=0.0001
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
N/A N=298 Hybrid Revascularization Observational Study
Coronary Artery Disease
Primary: Major Adverse Cardiac and Cerebrovascular Event (MACCE) — 23; 10; 3; 1 participants — p=0.80
N/A N=418 Observational Study of OCT in a Patients Undergoing FFR
Coronary Artery Disease
Primary: Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting — 0; 6.7; 6.2; 0.2 Percentage of per-subject incidence
N/A N=100 Coronary Orbital Atherectomy System Study
CAD
Primary: Major Adverse Cardiac Event (MACE) — 85.0 Percent Probability of Freedom from MACE
N/A N=88 Chronic Total Occlusion Crossing With the Wildcat Catheter
Peripheral Arterial Disease
Primary: Major Adverse Events — 4 participants